Background/Objectives: The aim of this study was to research and draw conclusions about the effect of a parenteral nutrition (PN) fat emulsion, rich in o-3 fatty acids, on the antioxidant markers of preterm infants, when compared with a standard fat emulsion. This was a double-blind, parallel-group study conducted in Athens, Greece, using an equal randomization method. Subjects/Methods: Thirty-eight infants were selected using a double-blind method and a computer-generated randomization list. Both groups received PN, based on the same protocols. Group A received SMOFlipid fat emulsion, while group B received the standard fat emulsion (Intralipid). Serum levels of vitamin A, E and total antioxidant potential (TAP) were measured on days 0, 7 and 14 of PN support. Clinical and biochemical data were collected on days 0, 14 and on the day of discharge. Results: Serum levels of vitamin E and A were significantly increased in group A, while only vitamin A serum level was increased in group B on the fourteenth day (group A: vitamin E: P-value ¼ 0.002, vitamin A: P-value ¼ 0.000, group B: vitamin E: P-value ¼ 0.065, vitamin A: P-value ¼ 0.000). TAP was increased only in the intervention group (group A: P-value ¼ 0.000, group B: P-value ¼ 0.287). Mild anemia was developed in both groups, while no differences were detected in the infection rate, days of hospitalization, days of ventilator support and days of phototherapy. Conclusions: Oxidative stress was significantly reduced in those neonates fed with o-3 fatty acids, whereas no effect was observed in the neonates fed with standard lipids. Intervention had no effect on infants' growth and clinical outcome.
Introduction
Oxidative stress is caused by the imbalance between the production of free radicals and the efficacy of the body's antioxidant system (Maltepe and Saugstad, 2009) . Free radicals are extremely unstable molecules, which are produced in the body during physiological metabolic processes. They tend to react with other molecules (polyunsaturated fatty acids of cell membranes, proteins, polysaccharides and nucleic acids), causing structural alterations on a molecular basis, functional abnormalities of the cell and tissue damage (Saugstad, 1996; Blackburn, 2005) .
Overproduction of free radicals can occur during the perinatal period because of ischemia-reperfusion, arachidonic acid cascade, free iron, nitric oxide cascade, phagocyte activation, hypoxia and hyperoxia (Saugstad, 2001) . Preterm neonates are more vulnerable to the effects of oxidative stress compared with term neonates. This is because of both their exposure to a highly hyperoxic environment and their immature antioxidant systems (Thibeault, 2000; Buonocore et al., 2002) . Oxidative stress in preterm neonates has a significant role in a number of morbidity conditions, mostly including respiratory distress syndrome, chronic lung diseases, retinopathy, intracranial hemorrhage and necrotizing enterocolitis (Sharda, 2006) . Therefore, one of the basic goals in the treatment of preterm infants is the minimization of oxidative stress, either by reducing the production of free radicals or by augmenting antioxidant defense mechanisms (Perrone et al., 2007) . The use of certain ingredients in parenteral nutrition (PN) formulas has been suggested as a method of enhancing neonates' antioxidant defense mechanisms (Yeung, 2006; Perrone et al., 2007) . Although o-3 polyunsaturated fatty acids have the ability to lower the potential for in vivo generation of free radicals, their ability to modulate oxidative stress in preterm infants through PN has not been assessed (Perrone et al., 2007) . Their use in PN formulas for preterm infants has been regarded as safe and well tolerated (Calder et al., 2010) .
The aim of this study was to assess the effect of an o-3-enriched PN lipid emulsion on the levels of antioxidant vitamins A and E, and total antioxidant potential (TAP) in preterm infants. The study was conducted applying a randomized, double-blind method, according to which preterm infants treated with standard lipid emulsions were the control group (Uauy and Hoffman, 2000; Gibson et al., 2001) . Preterm infants treated with SMOFlipid emulsion were the intervention group, for which the hypothesis was that there would be a reduction in oxidative stress.
Materials/subjects and methods

Study design
This was a double-blind, parallel-group study conducted in Athens, Greece, using an equal randomization method.
Subjects and settings
Infants born in the 'IASO' Maternity Hospital in Athens, and admitted in the neonates' intensive care unit (ICU) were candidates for inclusion in the study. The inclusion criteria were (a) gestational age o32 weeks, (b) birth weight o1500 g, (c) admission in the ICU within 12 h after birth, (d) 480% of total energy would be taken in through PN, during the first 8 days of life, (e) the fat administration through PN would be started on the second day of life at the latest, with the maximum lipid dose being 3 g/kg/day and (f) anticipated duration of PN would be 47 days. Exclusion criteria included (a) having inherited metabolic diseases, (b) having major congenital malformations, (c) having severe malformations of the visceral organs, kidneys, lungs or brain, (d) having participated in another drug research study (e) and having undergone transfusion of packed red blood cells and/ or fresh frozen plasma 415 ml/kg. All preterm neonates in the IASO ICU were treated with ampicillin and gentamicin for the first 10 days and then with amikacin and cefotaxime for the prevention of severe infections.
The Scientific and Ethical Committee of the 'IASO' Maternity Hospital approved the study protocol and the parents of the infants signed a consent form before the infants' enrolment in the study.
Sample size
Sample size calculation showed that in order to have a 0.8 power to detect a significant difference (P ¼ 0.05, two-sided) in the levels of antioxidant markers, 14 infants were required for each group.
Intervention
The preterm neonates were randomly divided into two groups, group A (intervention) and group B (control), and received the two different PN treatments starting from the day of birth (day 0).
Four protocols were created according to gestational age, birth weight, body weight in the beginning of the parenteral support and clinical condition (Skouroliakou et al., 2005) . These were integrated into a software so that they could be used for automatic calculations, design and production of individualized PN regimens and were based on the American Society of Parenteral and Enteral Nutrition(ASPEN) guidelines (ASPEN, 1993 ; National Advisory Group on Standards and Practice Guidelines for Parenteral Nutrition, 1997). For both subject groups, PN regimens were designed and automatically produced based on these protocols (Figure 1 ). Lipid emulsion was added in the PN solution on the first or second day of life, based on the gestational age. Macronutrients were provided, using the same products for glucose and amino acids solutions in both groups. Amino acids were derived from Vamin Infant (Fresenius Kabi HELLAS, Athens, Greece). The source of fat was different for each one of the two groups. Group A was administered SMOFlipid (Fresenius Kabi HELLAS), a formulation containing medium-chain triacylglycerols (30%), lipids from soya bean oil (30%), olive oil (25%) and fish oil (15%), while group B was administered the standard lipid formulation with lipids from soya bean oil (Intralipid 20%, Fresenius Kabi HELLAS, Athens, Greece). Infants in both groups received the PN solutions for a trial period of at least 14 days, at the end of which each infant started oral feedings.
Enteral feeding was initiated as soon as possible, as it is considered extremely important for the preterm neonates (Valentine and Puthoff, 2007) . However, the energy provided through oral feedings was o20% of the total energy intake for the trial period.
Data and sample collection
The neonatologists of the ICU assessed eligibility based on the inclusion and exclusion criteria. A statistician prepared a computer-generated randomization list, which was then given to the pharmacist, who was responsible for the placement of each infant in a group (intervention vs control) based on simple randomization procedures (the computergenerated randomization list) and the preparation of the different PN formulations in identical bags. The medical personnel provided the formulations. The statistician and the pharmacist did not participate in infants' care. All medical personnel and participants were blinded to treatment assignment during the whole course of the study.
The primary aim, with respect to the effect of the different types of lipid emulsions, was the reduction of oxidative stress in the intervention group as measured from specific antioxidant markers (vitamin A, E and TAP). The second aim was the evaluation of the effect of the different types of PN solutions on growth (body weight), blood count, clinical condition and length of hospitalization.
Collection and assessment of data was performed on day 0 (date of birth and initiation of PN), day 14 and at the time of discharge by the hospital. Collected data included anthropometry (weight, length and head circumference), biochemical tests, measurements of the levels of antioxidant vitamins and evaluation of TAP. TAP gives the total amount of radicals that can be cleared by an antioxidant or a biological sample through radical scavenging, prevention of radical formation and activation of antioxidant enzymes (Griffiths et al., 2002) . Weight was measured using a digital baby scale (WM2300, Weigh South, Asheville, NC, USA) with precision to 2 g, crown-heel length was measured using a neonatometer (Harpenden neonatometer, Holtain, Crymych, UK), and head circumference was measured with a non-stretch tape. Blood tests were performed 6 h after the cessation of enteral nutrition and included complete blood count (hematocrit levels, platelets, mean platelet volume and, white blood cells), C-reactive protein, bilirubin and creatinine levels. Vitamin E and A levels were measured in serum samples using HPLC techniques. An isocratic system was used, with a HPLC pump, injector and a UVdetector (AGILENT 1100, Agilent Technologies, Santa Clara, CA, USA) using the appropriate reagent kits (Chromsystems Instruments & Chemicals GmbH, Heimburgstr, Germany) for each reaction. Flow rate for vitamins A and E was 1.5 ml/ min. TAP was estimated using Bioxytech AOP-490 kit (OxisResearch, OXIS Health Products, Portland, OR, USA). Vitamin E, A and TAP were assessed on day 0, 7 and 14 of PN.
Medical data on gestational age, diagnosis, clinical conditions and medications were collected from the medical records. Heart rate, blood pressure and body temperature were monitored daily and recorded on days 0, 14 and at the time of discharge. Data on the clinical condition, infection rate, days of ventilation support and days of phototherapy were also collected. The number of days of PN support, as well as the total number of days of hospitalization, was recorded ( Figure 1 ).
Statistical analysis
An independent t-test was used to compare the demographic characteristics of the two groups at baseline (group A vs group B). A 2 Â 2 analysis of variance with repeated measures was used to assess the changes in the dependent variables between the two groups over time (day 0 to day 14, and day 0 to the day of discharge). The threshold for significance in all tests was set at P ¼ 0. Table 1 . Gestational age was lower in neonates of group A compared with those of group B. Body weight was o10th centile for gestational age in three infants of group A (21%) and four infants of group B (22%). There were no differences between the two groups with regard to birth weight, length and head circumference. All the other parameters were within normal ranges with the exception of blood pressure that was low. Levels of vitamin A and E were below normal in both groups. Body temperature, platelet concentration and vitamin A levels were higher in group A than in group B, while there were no differences between the two groups, with regard to other parameters. Based on the neonates' gestational age, lipid emulsion was included in the PN plan on their second day of life. There was no statistically significant difference between the two groups regarding the delivered constituents of PN (macroand micronutrients) ( Table 2) .
Three infants in group A and two in group B experienced an elevation in blood glucose levels up to a maximum of 200 mg/100 ml. In such cases, the reduction of glucose delivery rate is recommended by the hospital's protocol, so that blood glucose levels switch to the normal instantly. Therefore, glucose administration rate was decreased by 4 g/kg/day for a maximum of 3 days, until the blood glucose levels were normal and stable. Insulin was not administered in these cases of hyperglycemia.
The mean day of life for the onset of enteral nutrition (breast milk) was the same for both groups (group A: 8.56 ± 4.67 days, group B: 9.46 ± 5.12 days, P-value: 0.702). The volume and rate of administration were similar between the two groups (group A: 31.78±17.19 ml, group B: 21.03± 12.15 ml, P-value: 0.208, group A: 24.35 ± 10.49 ml/kg, group B: 16.76 ± 9.52 ml/kg, P-value: 0.136). In addition, enteral nutrition was o20% of total daily energy intake for the first 14 days of feeding.
Levels of vitamin E and TAP were significantly increased in group A, while in group B only vitamin A levels were significantly increased (P-value o0.05, data not shown) on the seventh day of the intervention. Table 3 presents the results of the intervention on the fourteenth day. Body weight was not significantly altered in any group. Blood pressure and heart rate were significantly increased in both groups and at the same rate. Hematocrit values were less in both the groups, again with no difference between them. Hematocrit values were below the normal ranges. Platelet values increased in both groups (within normal ranges), while white blood cell count increased in group A, but still remained within normal ranges. Creatinine decreased significantly in group B (within normal ranges). Regarding vitamin levels, significant differences were observed between the two groups. Vitamin E levels increased only in group A, whereas vitamin A levels increased in both groups. However, there was no significant difference between the two groups regarding vitamin E values, at the end of the fourteenth day. On the other hand, vitamin A values were higher in group A than in group B at the end of the fourteenth day. This could not be completely attributed to the different interventions x-3 effect on preterm neonates' oxidative stress M Skouroliakou et al because there was a significant difference between vitamin A values at the beginning of PN. Moreover, the repeated measures analysis revealed no time Â group effect for vitamin E and A levels. Interestingly, TAP was increased only in group A and the levels on the fourteenth day were significantly higher in group A than in group B. Moreover, significant time Â group effect was noticed regarding TAP levels (P-value ¼ 0.001). Total days of PN (group A: 41.00 ± 22.97, group B: 28.82 ± 13.93, P-value ¼ 0.148) and total days of hospitalization (group A: 54.00±24.81, group B: 58.94±21.55, P-value ¼ 0.559) were the same for both groups. Table 4 presents data for the neonates at the beginning of the PN and upon discharge. Body weight, length, head circumference, blood pressure and heart rate were significantly increased in both groups, but with no statistical significance between them. Hematocrit and creatinine values were decreased below normal ranges in both groups. There was no significant difference in the type, dose and duration of antibiotic therapy (group A: 39.50±22.69 days, group B: 45.94±19.17 days, P-value ¼ 0.398), the days of ventilation support (group A: 12.20 ± 8.18 days, group B: 9.11 ± 6.19 days, P-value ¼ 0.371), maximum inspired oxygen fraction (Group A: 0.54±0.16%, Group B: 0.57±0.19%, P-value ¼ 0.538) and the days of phototherapy between the two groups (group A: 6.36 ± 4.08 days, group B: 6.36 ± 3.10 days, P-value ¼ 1.000). None of the children, in any group, developed sepsis, and none manifested adverse effects attributed to the PN formulation.
Discussion
The primary aim of this study was to find the effects of o-3 polyunsaturated fatty acids on the antioxidant status of preterm infants, when they are administered through PN.
Intervention enhanced the antioxidant defense mechanisms in the group that received the o-3 lipid emulsion compared with the group that received the standard lipid emulsion.
In our sample, serum levels of vitamin A and E were below normal ranges at birth. This is commonly observed in preterm neonates, probably because of the fact that their adipose tissue stores are limited, and so are (Orzalesi, 1987; Debier, 2007; Gitto et al., 2009 ) the a-tocopherol concentrations (a-tocopherol normally accumulates during the third trimester of pregnancy) (Mactier and Weaver, 2005) . Both vitamins are regarded as important biological antioxidants and their supplementation in preterm neonates was documented many years ago (Orzalesi, 1987) . Vitamin E supplementation has been implicated in the prevention of bronchopulmonary dysplasia and elevations in hemoglobin levels in preterm neonates (Petrich et al., 1976) , while vitamin A has been shown to prevent chronic lung disease, bronchopulmonary dysplasia and sepsis (Tyson et al., 1999; Atkinson, 2001; Darlow and Graham, 2007) . In this study, both groups were supplemented with the same dose of fatsoluble vitamins. However, only the group that received o-3 fatty acids increased their vitamin E serum levels. o-3 fatty acids may have enhanced the increase of vitamin E levels through the reduction of oxidative stress. Nevertheless, on the fourteenth day, levels of vitamin E were not different between the two groups, despite the fact that group A had lower vitamin E levels at baseline (not statistically significant). Therefore, it seems that the intervention had a possible modest effect on vitamin E, although the interpretation of the rise of vitamin E levels in group A is complex. On the contrary, in the same pattern, vitamin A level was increased in both the groups. Therefore, the intervention did not seem to have any effect on vitamin A status. Its increase could be attributed to the supplementation with fat-soluble vitamins. The significant difference in vitamin A levels between the two groups on the fourteenth day probably lies in the fact that serum levels of vitamin A were higher in group A since birth. The most interesting outcomes of the study were in regard to the changes in TAP levels. These were increased only in the group that received o-3 fatty acids and at the fourteenth day they were significantly higher in this group compared with the group that received the standard lipid emulsion. The significant time Â group effect on TAP levels confirms the antioxidant effect of o-3 fatty acids. TAP is a strong indicator of the body's antioxidant defense potential. When oxidative stress is reduced, the body does not consume its antioxidant molecules and therefore these are anticipated to accumulate in the blood. Thus, the increase in TAP levels verified the reduction of oxidative stress, and as this was observed only in the intervention group, it could be assumed that o-3 fatty acids were responsible for the reduction of oxidative stress.
We are not aware of any studies in which o-3 fatty acids have been used in lipid emulsions for PN, aiming at suppressing oxidative stress in preterm neonates. In accordance with our study, Antebi et al. (2004) showed that the use of the o-3-enriched fat emulsion SMOFlipid, in critically ill adult patients receiving PN increased the levels of antioxidant vitamins (especially vitamin E). Many randomized clinical trials have assessed the effect of o-3 fatty acid supplementation in terms of visual and neural development in preterm infants and have shown that o-3 fatty acids have a positive effect on these parameters. However, their effect on oxidative stress had not been assessed (Gibsona et al., 2001) . These results may be generalized to other preterm infant populations as the study sample included both sexes and a variety of clinical conditions. Moreover, the population was derived from a large maternity hospital, where a significant proportion of preterm neonates from the whole country are born.
Growth was not affected by the intervention. Moreover, there was no significant difference between the two groups with regard to the clinical characteristics. Neonates in both groups developed mild anemia prematurely, which is a common finding in preterm neonates (Salsbury, 2001) . Finally, the intervention had no effect on their clinical outcome, as there were no differences between the groups regarding infection rate, days of hospitalization, days of ventilation support and days of phototherapy.
A limitation of the study was the small size of sample studied. The recruitment of a larger number of participants was extremely difficult because of the characteristics of the population and the severity of the exclusion criteria. Another limitation was the assessment of a small number of biomarkers of oxidative stress, a fact that could limit the interpretation of the results. However, the amount of blood available for our research was limited because of the age of the candidates studied.
In conclusion, administration of an o-3-enriched PN fat emulsion resulted in significant increase in vitamin E and TAP levels in preterm neonates during a 14-day period of monitoring. Thus, the intervention resulted in decrease in the oxidative stress because of the antioxidant effect of o-3 fatty acids. No effects of o-3 fatty acids were observed regarding growth and clinical outcomes. These results have to be verified through other studies using a larger number of samples.
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